Quarterly report [Sections 13 or 15(d)]

Accounts Payable and Accrued Expenses (Details)

v3.26.1
Accounts Payable and Accrued Expenses (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 30, 2026
Feb. 28, 2026
Jun. 30, 2025
Mar. 31, 2026
Dec. 31, 2024
Dec. 31, 2025
Accounts Payable and Accrued Expenses [Line Items]            
Accounts payable       $ 14,139,000   $ 14,238,000
Accrued expenses:            
Professional fees       6,971,000   1,055,000
Salaries, bonus and related benefits       7,381,000   7,880,000
Research and development       355,000   277,000
Accrued royalties payable       1,863,000   1,805,000
Accrued coupons and rebates       14,770,000   16,547,000
Return reserve       2,508,000   2,177,000
Cyprium payment owed to NIH1       41,000,000   0
Other       3,999,000   3,146,000
Total accounts payable and accrued expenses       92,986,000   47,125,000
Mustang | uBriGene (Boston) Biosciences, Inc.            
Accrued expenses:            
Other       1,300,000 $ 1,300,000  
Accrued Interest       50,000    
Upfront payment       $ 100,000    
Interest rate on outstanding liability     5.00%      
Mustang | uBriGene (Boston) Biosciences, Inc. | Maximum            
Accrued expenses:            
Net assets           $ 20,000,000
Mustang | uBriGene (Boston) Biosciences, Inc. | If Mustang's net assets are below $20 million            
Accrued expenses:            
Additional payment period         6 months  
Net assets         $ 20  
Cyprium            
Accrued expenses:            
Consideration received   $ 205,000,000        
Cyprium | PRV APA            
Accrued expenses:            
Consideration received $ 205,000,000 $ 205,000,000        
Cyprium | PRV APA | Eunice Kennedy Shriver National Institute of Child Health and Human Development            
Accrued expenses:            
Percentage of proceeds obligated to pay 2.50% 20.00%   20.00%    
Gross proceeds $ 5,100,000 $ 41,000,000   $ 41,000,000